Compare Abeona Therapeutics Inc (ABEO) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs JPMorgan Chase & Co — how do they compare? Abeona Therapeutics Inc trades at $7.55 (market cap $424.33M), while JPMorgan Chase & Co trades at $362.11 (market cap $956.39B). The key difference: JPMorgan Chase & Co is far larger — about 2253.9× Abeona Therapeutics Inc's market cap, and JPMorgan Chase & Co pays a 1.67% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | JPM | |
|---|---|---|
Market Cap | $424.33M | $956.39B |
Sector | Health | Financials |
52-Week High | $7.45 | $359.79 |
52-Week Low | $4.17 | $282.84 |
Enterprise Value | $279.23M | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
JPMorgan Chase & Co. (JPM) trades at $361.15, up 1.02% today, with a bullish technical signal from moving averages and a consensus analyst price target of $374.18. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth from $181.85B in 2025 to $194.9B projected for 2026. The stock shows strong profitability with a net income margin of 33.38% and ROE of 18.43%, though cash flow trends indicate operational outflows.
Outlook remains positive due to earnings momentum and institutional support, but risks include geopolitical tensions affecting oil prices and cybersecurity threats highlighted in recent news. The stock's valuation at a P/E of 15.42 offers room for growth, but investors should monitor debt levels and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
